BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37108958)

  • 21. The efficacy and safety of intravitreal injection of Ranibizumab as pre-treatment for vitrectomy in proliferative diabetic retinopathy with vitreous hemorrhage.
    Li S; Yang Y; Zou J; Zeng J; Ding C
    BMC Ophthalmol; 2022 Feb; 22(1):63. PubMed ID: 35139812
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preoperative Intravitreal Conbercept Facilitates Vitrectomy in Proliferative Diabetic Retinopathy: Is Attention Required for the Fellow Eye?
    Xu W; Cheng W; Yao Y; Guo J; Xu G
    J Ophthalmol; 2019; 2019():2923950. PubMed ID: 31467691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravitreal ranibizumab versus vitrectomy for recurrent vitreous haemorrhage after pars plana vitrectomy for proliferative diabetic retinopathy: a prospective study.
    Chatziralli I; Dimitriou E; Theodossiadis G; Bourouki E; Bagli E; Kitsos G; Theodossiadis P
    Int Ophthalmol; 2020 Apr; 40(4):841-847. PubMed ID: 31788713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Minimally invasive vitrectomy for the treatment of severe proliferative diabetic retinopathy].
    Zheng CZ; Ren XJ; Ke YF; Wen DJ; Li XR
    Zhonghua Yan Ke Za Zhi; 2021 Jun; 57(6):440-446. PubMed ID: 34098693
    [No Abstract]   [Full Text] [Related]  

  • 25. Endodiathermy plus photocoagulation as treatment of sclerotomy site vascularization secondary to pars plana vitrectomy for proliferative diabetic retinopathy.
    Nadal J; Carreras E; Canut MI
    Retina; 2012 Jul; 32(7):1310-5. PubMed ID: 22466471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravitreal conbercept injection with panretinal photocoagulation for high-risk proliferative diabetic retinopathy with vitreous hemorrhage.
    Xu Y; Ye Q; Shen W
    Int J Ophthalmol; 2024; 17(6):1066-1072. PubMed ID: 38895681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy.
    di Lauro R; De Ruggiero P; di Lauro R; di Lauro MT; Romano MR
    Graefes Arch Clin Exp Ophthalmol; 2010 Jun; 248(6):785-91. PubMed ID: 20135139
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low expression of RBP4 in the vitreous humour of patients with proliferative diabetic retinopathy who underwent Conbercept intravitreal injection.
    Wen D; Ren X; Li H; He Y; Hong Y; Cao J; Zheng C; Dong L; Li X
    Exp Eye Res; 2022 Dec; 225():109197. PubMed ID: 35932904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Efficacy of Preoperative and Intraoperative Intravitreal Ranibizumab as Adjuvant Therapy of Ahmed Glaucoma Valve Implantation Combined with Vitrectomy in the Management of Neovascular Glaucoma with Diabetic Vitreous Hemorrhage.
    Gao S; Lin Z; Zhong Y; Shen X
    J Pers Med; 2023 Dec; 14(1):. PubMed ID: 38248719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment.
    Oshima Y; Shima C; Wakabayashi T; Kusaka S; Shiraga F; Ohji M; Tano Y
    Ophthalmology; 2009 May; 116(5):927-38. PubMed ID: 19269033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term outcomes of administration of intravitreal triamcinolone acetonide after posterior vitreous detachment during pars plana vitrectomy for proliferative diabetic retinopathy.
    Liao M; Huang Y; Wang J; Meng X; Liu Y; Yu J; Yan H
    Br J Ophthalmol; 2023 Apr; 107(4):560-564. PubMed ID: 34844917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intraocular VEGF level as a risk factor for postoperative complications after vitrectomy for proliferative diabetic retinopathy.
    Wakabayashi Y; Usui Y; Okunuki Y; Ueda S; Kimura K; Muramatsu D; Kezuka T; Goto H
    Invest Ophthalmol Vis Sci; 2012 Sep; 53(10):6403-10. PubMed ID: 22899753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of prophylactic intravitreal bevacizumab injection to proliferative diabetic retinopathy patients with elevated preoperative intraocular VEGF in preventing complications after vitrectomy.
    Tsubota K; Usui Y; Wakabayashi Y; Suzuki J; Ueda S; Goto H
    Clin Ophthalmol; 2019; 13():1063-1070. PubMed ID: 31303746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognosis value of Chinese Ocular Fundus Diseases Society classification for proliferative diabetic retinopathy on postoperative visual acuity after pars plana vitrectomy in type 2 diabetes.
    Lin TZ; Kong Y; Shi C; Eric Pazo E; Dai GZ; Wu XW; Xu L; Shen LJ
    Int J Ophthalmol; 2022; 15(10):1627-1633. PubMed ID: 36262848
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravitreal triamcinolone acetonide as an additional tool in pars plana vitrectomy for proliferative diabetic retinopathy.
    Jonas JB; Söfker A; Degenring R
    Eur J Ophthalmol; 2003 Jun; 13(5):468-73. PubMed ID: 12841570
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy comparison of intravitreal injections of conbercept and ranibizumab for severe proliferative diabetic retinopathy.
    Lu Q; Lu L; Chen B; Chen W; Lu P
    Can J Ophthalmol; 2019 Jun; 54(3):291-296. PubMed ID: 31109466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy.
    Ahn J; Woo SJ; Chung H; Park KH
    Ophthalmology; 2011 Nov; 118(11):2218-26. PubMed ID: 21724263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimal timing of preoperative intravitreal anti-VEGF injection for proliferative diabetic retinopathy patients.
    Xu Y; Xie C; Fang Y; Yu Y; Qiu C
    Int J Ophthalmol; 2022; 15(10):1619-1626. PubMed ID: 36262859
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vitreous concentrations of vascular endothelial growth factor as a potential biomarker for postoperative complications following pars plana vitrectomy.
    Nisic F; Jovanovic N; Mavija M; Alimanovic-Halilovic E; Nisic A; Lepara O; Cemerlic A
    Arch Med Sci; 2019 Mar; 15(2):449-456. PubMed ID: 30899298
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monitoring intraocular proangiogenic and profibrotic cytokines within 7 days after adjunctive anti-vascular endothelial growth factor therapy for proliferative diabetic retinopathy.
    Hu Z; Cao X; Chen L; Su Y; Ji J; Yuan S; Fransisca S; Mugisha A; Zou W; Xie P; Liu Q
    Acta Ophthalmol; 2022 May; 100(3):e726-e736. PubMed ID: 34260829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.